|
gptkbp:instance_of
|
gptkb:vaccine
|
|
gptkbp:administration_schedule
|
single dose
|
|
gptkbp:antibody_response
|
neutralizing antibodies
|
|
gptkbp:approves
|
gptkb:2020
|
|
gptkbp:average_temperature
|
2 to 8 degrees Celsius
|
|
gptkbp:clinical_trial
|
gptkb:China
over 40,000
Phase 3
positive results
|
|
gptkbp:developed_by
|
gptkb:Can_Sino_Biologics
|
|
gptkbp:dosage_form
|
gptkb:1
not required
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Ad5-n Co V
|
|
gptkbp:is_effective_against
|
approximately 65%
|
|
gptkbp:is_vulnerable_to
|
gptkb:educational_campaigns
gptkb:recombinant_vaccine
March 2021
international partnerships
ongoing studies
rapid development
post-marketing surveillance
government and private sector
strong immune response
limited to certain regions
involvement of local communities
viral vector platform
contributes to herd immunity
reduces severe disease
established logistics
conducted in multiple phases
adverse event reporting system
single injection
aims to reduce COVID-19 transmission
|
|
gptkbp:manufacturer
|
gptkb:Can_Sino_Biologics
|
|
gptkbp:market_position
|
available in China
|
|
gptkbp:mechanism_of_action
|
uses adenoviral vector
|
|
gptkbp:production_volume
|
millions of doses
|
|
gptkbp:publication
|
published in The Lancet
|
|
gptkbp:regulatory_compliance
|
gptkb:China_National_Medical_Products_Administration
|
|
gptkbp:route_of_administration
|
intramuscular
|
|
gptkbp:safety_features
|
generally safe
|
|
gptkbp:side_effect
|
mild to moderate reactions
|
|
gptkbp:target_audience
|
adults
|
|
gptkbp:targets
|
gptkb:SARS-Co_V-2_spike_protein
gptkb:COVID-19
|
|
gptkbp:type
|
viral vector vaccine
|
|
gptkbp:vaccine_approval_authority
|
NMPA
|
|
gptkbp:vaccine_clinical_trial_phases
|
Phase 1, Phase 2, Phase 3
|
|
gptkbp:vaccine_community_feedback
|
gathering public opinions
|
|
gptkbp:vaccine_crisis_response
|
rapid deployment during outbreaks
|
|
gptkbp:vaccine_cultural_sensitivity
|
consideration of local customs
|
|
gptkbp:vaccine_distribution_strategy
|
focused on high-need areas
|
|
gptkbp:vaccine_efficacy_duration
|
at least 6 months
|
|
gptkbp:vaccine_efficacy_study
|
ongoing efficacy studies
|
|
gptkbp:vaccine_ethical_considerations
|
informed consent required
|
|
gptkbp:vaccine_global_distribution
|
expanding access globally
|
|
gptkbp:vaccine_health_equity
|
aims to reach underserved populations
|
|
gptkbp:vaccine_impact_assessment
|
ongoing evaluations
|
|
gptkbp:vaccine_long_term_studies
|
planned for future research
|
|
gptkbp:vaccine_public_health_goal
|
control the pandemic
|
|
gptkbp:vaccine_public_health_partnerships
|
collaboration with NGOs
|
|
gptkbp:vaccine_regulatory_compliance
|
meets safety standards
|
|
gptkbp:vaccine_research_institutions
|
collaborating universities
|
|
gptkbp:vaccine_research_outcomes
|
data published in journals
|
|
gptkbp:vaccine_storage_requirements
|
standard refrigeration
|
|
gptkbp:vaccine_target_group
|
high-risk populations
|
|
gptkbp:whoemergency_use_listing
|
yes
|
|
gptkbp:bfsParent
|
gptkb:Can_Sino_Biologics
|
|
gptkbp:bfsLayer
|
6
|